Takeda Pharmaceutical Company Limited has scheduled its earnings announcement for 29 October 2026. In the first quarter of the fiscal year ending July 2026, revenue was ¥1.2199 trillion, operating profit was ¥201.4 billion and quarterly profit attributable to owners of the parent was ¥113.2 billion, representing higher revenue and operating profit but a decline in quarterly profit due to a higher tax burden.
Takeda Pharmaceutical Company Limited's next earnings announcement is scheduled for 29 October 2026. According to the latest earnings summary, revenue increased 10.2% year on year to ¥1.2199 trillion and operating profit rose 9.1% to ¥201.4 billion. However, a substantial increase in corporate income tax expense caused quarterly profit attributable to owners of the parent to fall 8.9% to ¥113.2 billion. The full-year forecast remains unchanged.
Performance has been on an improving trend over the past 12 quarters, with continued improvements in net profit and operating profit margins, a stable equity ratio, and generally rising revenue and EPS. Future performance checkpoints include increased demand for core products and the penetration of new products, while risks include the penetration of generic products and the impact of drug prices and reimbursement systems.
Positive factors highlighted in the earnings summary include growth in ENTYVIO, stable demand for immunoglobulin, growth in oncology, penetration of new products for rare diseases, progress in generic development and lower amortisation expenses. Risks listed include intensifying competition from generic products, the impact of the drug pricing system, higher transformation costs, increased legal costs and foreign exchange effects.